Company Announcements

Latest announcements

Date and timeCompanyHeadlineSource
Media Alert: Rambus to Showcase High-performance SerDes Solutions at the eSilicon Live Seminars in Tokyo and ShanghaiBusiness Wire
Celanese Opens Customer Solution Center in TokyoBusiness Wire
AstraZeneca’s CALQUENCE® (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukemia TrialsBusiness Wire
Algeco Scotsman
Algeco Scotsman Announces Debt Package for Refinancing, Acquisition of Touax Solutions Modulaires SAS and Exercise of Put Option OMX
bluebird bio Presents New Data from Clinical Studies of LentiGlobin™ Gene Therapy in Transfusion-Dependent β-Thalassemia at American Society of Hematology Annual MeetingBusiness Wire
bluebird bio Announces Updated Clinical Results from Ongoing Phase 1 Multicenter Study of LentiGlobin™ Gene Therapy in Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual MeetingBusiness Wire
Verastem Announces Clinical Data from the Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaBusiness Wire
Exclusive: Today, 9 December 2017, Artprice confirms that the acquisition of Da Vinci's Salvator Mundi involved geopolitical mediation, and that the Vatican Museums did indeed study the offer OMX
Brøndbyernes IF Fodbold A/S – Aftale med Alexander Zorniger forlængesOMX
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer OMX
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual MeetingBusiness Wire
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell LymphomaBusiness Wire
Study Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection and Target Joint Resolution in People with Hemophilia ABusiness Wire
Syros Announces New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Pointing to a Potential Biomarker of Response and Combination ApproachBusiness Wire
Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS PatientsBusiness Wire
Seattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma at ASH Annual MeetingBusiness Wire
Kadmon Presents Updated Positive Phase 2 Data on KD025 in cGVHD at ASH Annual MeetingBusiness Wire
Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of HematologyBusiness Wire
Phase II Data Showed Genentech’s Investigational Polatuzumab Vedotin Plus Bendamustine and Rituxan (BR) Increased Complete Response Rates Compared to BR Alone in Previously Treated Aggressive LymphomaBusiness Wire
Thomas Fire Leads to Santa Barbara Area OutageBusiness Wire
RNS announcements are delayed by up to an hour.
  • 1
  • 2
  • 3
  • 375
  • 376
  • 377